Lacosamide (LCM), a novel drug with the reduction of HDAC1 protein expression in preclinical studies as mentioned above, was licensed in 2008 by FDA/EMA as an adjunctive treatment for curing partial-onset seizures in adolescent patients attacked by epilepsy. Here, HDAC1 is linked to epilepsy.